Form 4: Roivant CFO Sells Shares After Option Exercise

Roivant Sciences CFO Richard Pulik exercised stock options and subsequently sold a portion of his common shares on December 23, 2025.

Summary

• Richard Pulik, CFO of Roivant Sciences Ltd., engaged in transactions involving the company's common shares on December 23, 2025.
• Pulik exercised stock options to acquire 260,000 common shares at an exercise price of $3.85 per share.
• Concurrently, he sold 260,000 common shares at a weighted average price of $22.45 per share, with prices ranging from $22.37 to $22.51.
• Additionally, Pulik sold another 146,731 common shares at a weighted average price of $22.39 per share, with prices ranging from $22.28 to $22.54.
• Following these transactions, Pulik directly beneficially owns 239,413 common shares and 740,000 stock options.
• The stock options exercised were part of an award with a vesting commencement date of April 20, 2022, vesting 25% on the first anniversary and then in 36 equal monthly installments thereafter, subject to continuous service.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving option exercise and subsequent share sales, which is a common compensation event. It does not inherently indicate positive or negative sentiment about the company's future, especially given it was made pursuant to a Rule 10b5-1 plan.

Positives

• The CFO realized a significant gain from exercising options at $3.85 and selling shares at an average of approximately $22.45, indicating the company's stock appreciation since the option grant.
• The transactions were made pursuant to a Rule 10b5-1 plan, suggesting a pre-arranged, non-discretionary sale rather than a reaction to immediate market conditions.

Negatives

• Insider selling, even when pre-arranged, can sometimes be perceived negatively by the market, potentially signaling a lack of further upside from the insider's perspective.
• The sale of 406,731 shares represents a substantial portion of the shares acquired through the option exercise and additional holdings.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's compensation realization.

Stakeholder Impact

• Shareholders: May observe the CFO's decision to sell a significant number of shares, which could be interpreted in various ways, though the Rule 10b5-1 plan mitigates concerns about opportunistic selling.
• Management: The CFO realized substantial personal gains from long-term equity compensation.

Key Dates

Keywords

Roivant Sciences, ROIV, Richard Pulik, CFO, Insider Trading, Form 4, Stock Options, Share Sale, Equity Compensation, Rule 10b5-1